List of Excipients in Branded Drug TIAZAC

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	TIAZAC	diltiazem hydrochloride	0187-2612	CELLULOSE, MICROCRYSTALLINE
Bausch Health US LLC	TIAZAC	diltiazem hydrochloride	0187-2612	D&C RED NO. 28
Bausch Health US LLC	TIAZAC	diltiazem hydrochloride	0187-2612	ETHYL ACRYLATE AND METHYL METHACRYLATE COPOLYMER

Tiazac Excipient Strategy and Commercial Opportunities in Extended-Release Diltiazem

Last updated: September 8, 2026

Tiazac is an extended-release diltiazem hydrochloride capsule based on multiparticulate coated beads. Its commercial value is no longer protected by meaningful new-drug exclusivity. The strongest opportunities are in generic substitution, differentiated extended-release performance, lower-cost excipient systems, capsule presentation, and contract development of diltiazem modified-release products.

The formulation challenge is maintaining controlled diltiazem release across the full dosing interval while matching the reference product in dissolution, food effect, pharmacokinetics, and dose proportionality. Excipient selection therefore has direct regulatory and commercial importance.

What is Tiazac and how is it formulated?

Tiazac is a once-daily extended-release capsule containing diltiazem hydrochloride. The product has been marketed in 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg strengths. It is indicated for hypertension and chronic stable angina. The capsule contains coated drug-loaded beads designed to release diltiazem gradually after oral administration (Bausch Health, n.d.; DailyMed, 2024).

Tiazac is not a simple matrix tablet. Its multiparticulate architecture provides several development advantages:

• More uniform gastrointestinal distribution than a single tablet.
• Reduced sensitivity to local pH conditions.
• Lower risk that one damaged dosage unit will release the entire dose.
• A platform for adjusting release through coating thickness and polymer permeability.
• Potential for dose scaling by changing bead loading or capsule fill weight.

The reference product label instructs patients to swallow the capsule whole and not crush or chew it. That instruction indicates that the release-controlling structure is integral to the dosage form.

Typical excipient functions in Tiazac-type products

The exact composition of a generic product does not need to replicate the reference product excipient-for-excipient. It must, however, demonstrate pharmaceutical equivalence and bioequivalence under the applicable abbreviated new drug application pathway.

Formulation element	Typical function	Commercial importance
Diltiazem hydrochloride	Active pharmaceutical ingredient	High-dose load and release-rate driver
Sugar or microcrystalline starter cores	Substrate for drug layering	Controls bead size and coating uniformity
Hydroxypropyl methylcellulose or povidone	Binder and drug-layering aid	Affects adhesion, assay uniformity, and process yield
Ethylcellulose or comparable insoluble polymer	Rate-controlling membrane	Main release-control material
Talc or other anti-tacking agent	Prevents bead agglomeration during coating	Important for continuous coating and yield
Plasticizer	Improves polymer-film flexibility	Reduces cracking and dissolution drift
Gelatin or hypromellose capsule shell	Dosage-form enclosure	Controls appearance, stability, and supply cost
Titanium dioxide and colorants	Opacity and product identification	Supports strength differentiation and branding

The reference label identifies inactive ingredients for the marketed capsule strengths. A generic sponsor should treat the label as a starting point rather than a complete formulation blueprint because manufacturing conditions, polymer grade, coating weight gain, bead size distribution, and drug-layer uniformity can materially change release performance.

What excipient strategy best matches Tiazac?

A robust strategy is to use a drug-layered bead core with an aqueous or organic polymer coating system and a capsule fill process that produces narrow bead-size distribution.

Drug-layering strategy

Diltiazem hydrochloride is highly water soluble. High solubility increases the risk of rapid diffusion through an inadequately controlled membrane. The drug layer should therefore be designed for:

• Uniform distribution over the starter core.
• Controlled surface roughness.
• Adequate binder concentration.
• Low agglomeration during fluid-bed processing.
• Consistent drug loading across the capsule fill.

Povidone and hypromellose are conventional choices for drug layering. Povidone can provide strong adhesion but may increase wettability and accelerate release if used at excessive levels. Hypromellose can provide both binding and additional diffusion resistance.

Rate-controlling membrane

Ethylcellulose is the most commercially logical starting polymer for a Tiazac-type system. It is insoluble in gastrointestinal fluid and can be combined with a water-soluble pore former to adjust permeability. The principal formulation variables are:

1. Polymer-to-drug ratio.
2. Coating weight gain.
3. Pore-former concentration.
4. Plasticizer level.
5. Bead diameter.
6. Coating curing conditions.
7. Capsule fill-weight variation.

A pore-former such as hypromellose or a water-soluble polymer can create diffusion channels through the ethylcellulose film. Increasing pore former generally accelerates release. Increasing ethylcellulose coating weight generally slows release, although the relationship is not linear across all processing conditions.

The principal development risk is release drift caused by coating defects, polymer variability, or incomplete curing. Generic sponsors should establish dissolution specifications that are sufficiently discriminating to detect coating changes without creating unnecessary batch failures.

Alternative polymer systems

Commercial alternatives include:

• Hypromellose-based hydrophilic matrices applied to pellets.
• Ammonio methacrylate copolymers.
• Ethylcellulose dispersion systems.
• Combination coatings using insoluble polymer and water-soluble pore formers.
• Hot-melt or solvent-free coating processes.

A polymer substitution can create a meaningful differentiation opportunity, but it also increases the risk of a complex bioequivalence program. The lowest-risk path is usually a formulation that preserves the multiparticulate release mechanism while optimizing excipient grade, coating efficiency, and cost.

What generic opportunities exist for Tiazac?

The principal opportunity is a generic extended-release diltiazem capsule with equivalent pharmacokinetic exposure and comparable in vitro release. Diltiazem is an established calcium-channel blocker with broad prescriber familiarity and multiple approved dosage forms.

Generic developers can pursue several commercial positions:

Opportunity	Product concept	Primary advantage
Standard ANDA	Direct Tiazac-equivalent capsule	Lowest clinical development burden
Low-cost platform	Simplified bead coating and high-throughput encapsulation	Manufacturing margin
Strength portfolio	120 mg through 360 mg capsules	Pharmacy substitution coverage
Sprinkle or alternate administration	Beads suitable for selected administration options	Patient convenience, subject to labeling
Specialty generic	Controlled-release product with differentiated packaging or adherence support	Lower direct price competition
Contract manufacturing	Diltiazem ER bead platform supplied to multiple sponsors	Asset utilization and licensing revenue

The best near-term opportunity is a conventional ANDA product with a narrow manufacturing cost base. A differentiated product may command a better commercial position, but it must justify added regulatory, clinical, and manufacturing complexity.

What is the FDA regulatory status of Tiazac and its generic competitors?

Tiazac is an FDA-approved prescription extended-release diltiazem product. Generic extended-release diltiazem capsules have been approved through the ANDA pathway. The relevant regulatory objective is pharmaceutical equivalence and bioequivalence to the selected reference listed drug.

FDA review is likely to focus on:

• Strength and dosage-form equivalence.
• In vitro dissolution across multiple media and time points.
• Fasting and fed pharmacokinetic studies where required.
• Dose proportionality across strengths or a justified biowaiver strategy.
• Alcohol-induced dose dumping.
• Stability of the coated bead system.
• Capsule content uniformity.
• Manufacturing controls for coating weight gain and bead-size distribution.

FDA guidance for modified-release solid oral dosage forms places particular emphasis on food effects, dissolution behavior, and the relationship between formulation changes and systemic exposure (U.S. Food and Drug Administration, 2019).

Orange Book and exclusivity position

Tiazac has no practical remaining new chemical entity exclusivity. Diltiazem hydrochloride has been used clinically for decades, and generic extended-release products are established in the U.S. market.

The relevant protection analysis is therefore:

Protection category	Tiazac position
NCE exclusivity	Expired
Pediatric exclusivity	No current commercial relevance
Original formulation patents	Expired or commercially non-blocking
Current formulation patents	Must be assessed against the specific reference listing and applicant formulation
Method-of-use patents	Limited practical impact for established hypertension and angina indications
REMS or restricted distribution	Not a principal barrier
Biosimilar protection	Not applicable

An applicant should conduct a current Orange Book patent and exclusivity review before filing. The commercial risk is more likely to come from formulation performance, manufacturing scale, and price competition than from a new Tiazac patent blockade.

Are Paragraph IV challenges and patent litigation material for Tiazac?

Paragraph IV risk is generally limited for an old diltiazem product because the original protection period has elapsed and multiple generic products have entered the market. A new applicant could still make a Paragraph IV certification against a listed formulation or method patent if one remains relevant, but that would not normally define the market opportunity.

The more important legal questions are:

• Whether the proposed product relies on a listed reference product.
• Whether any unexpired patent claims cover the bead structure, coating composition, or release profile.
• Whether the applicant’s excipient system avoids claim elements.
• Whether a patent owner could assert a process or formulation claim despite the absence of meaningful market exclusivity.
• Whether a 30-month stay or settlement could delay launch.

There is no biosimilar litigation issue because Tiazac is a small-molecule drug, not a biologic. Litigation risk should be assessed through current FDA Orange Book listings and USPTO records rather than inferred from the historical Tiazac brand name.

What formulation patents could protect a new diltiazem ER product?

A new product could seek protection around a technically differentiated system rather than the active ingredient. Potential claim areas include:

Release-control composition

Claims may target:

• Specific ratios of diltiazem to ethylcellulose.
• Defined pore-former concentrations.
• Polymer combinations.
• Plasticizer selection.
• Coating weight ranges.
• Alcohol-resistant release behavior.

Multiparticulate architecture

Claims may cover:

• Bead diameter distribution.
• Drug-layer thickness.
• Sequential coating layers.
• Immediate-release and extended-release bead populations.
• Capsule compositions containing multiple release fractions.

Manufacturing method

Process claims may address:

• Fluid-bed coating parameters.
• Spray rate and inlet temperature.
• Curing conditions.
• Solvent-free coating.
• Continuous coating and encapsulation.
• In-process controls tied to dissolution performance.

Product-by-process and performance claims

A sponsor could pursue claims defined by:

• Dissolution at specified time points.
• Pharmacokinetic exposure ranges.
• Reduced food effect.
• Reduced alcohol dose dumping.
• Defined release under simulated gastrointestinal conditions.

Performance claims can be difficult to enforce if competing products achieve the same profile through different compositions. Composition and process claims normally provide a more direct enforcement position.

How strong is the Tiazac patent estate?

The legacy estate is weak as a source of market exclusivity because the active ingredient and original extended-release concepts are old. A new patent estate could still have moderate value if it protects a reproducible manufacturing process or a clinically meaningful release profile.

Patent asset	Estimated commercial strength
Diltiazem compound patent	None for current market protection
Broad extended-release concept	Low, due to prior art
Specific bead coating composition	Moderate if narrowly drafted and difficult to design around
Alcohol-resistant formulation	Moderate if supported by strong comparative data
Low-food-effect formulation	Moderate, subject to clinical relevance
Manufacturing process	Moderate to high if it materially lowers cost or improves consistency
Capsule color or packaging	Low
New indication method patent	Low to moderate, depending on claim scope and clinical data

The strongest defensible position is likely a formulation-process combination supported by comparative dissolution, pharmacokinetic, stability, and manufacturing-cost data.

What commercial opportunities exist in excipient supply?

Excipient suppliers can participate in the Tiazac value chain without owning the finished drug product. The main opportunities are specialized grades of:

• Ethylcellulose or other sustained-release polymers.
• Hypromellose and povidone for drug layering.
• Anti-tacking agents.
• Plasticizers.
• Starter cores.
• Hard capsules.
• Ready-to-use coating dispersions.
• Multiparticulate manufacturing services.

A supplier with a validated coating system can create switching costs by supplying both the polymer and process knowledge. The value proposition is strongest when the supplier can show consistent dissolution across commercial-scale batches, reduced coating time, lower solvent use, and improved yield.

Manufacturing and intellectual-property barriers

The active ingredient is not the main barrier. The practical barriers are:

• Uniform layering of a highly soluble drug.
• Consistent membrane coating at commercial scale.
• Control of bead agglomeration.
• Reproducible release after storage.
• Scale-up from development fluid-bed equipment.
• Reliable supply of specialty polymer grades.
• Demonstration of bioequivalence against the reference product.
• Control of dose dumping under alcohol challenge conditions.

A manufacturer that has already commercialized pellet-based modified-release products has a meaningful advantage. The platform technology, rather than diltiazem itself, is the principal source of development leverage.

How does Tiazac compare with other diltiazem extended-release products?

Tiazac competes with several diltiazem modified-release presentations, including once-daily capsules and tablets marketed under different brand and generic names. Products are not automatically substitutable merely because they contain the same active ingredient and nominal daily dose.

Product type	Release architecture	Main development issue
Tiazac-type capsule	Multiparticulate coated beads	Match bead dissolution and pharmacokinetics
Cardizem CD-type capsule	Extended-release beads or granules	Product-specific bioequivalence
Dilacor XR-type product	Modified-release capsule	Different release profile and labeling
Extended-release tablet	Hydrophilic or insoluble matrix	Tablet-specific food and dissolution behavior
Immediate-release tablet	Rapid release, multiple daily dosing	Not a direct substitute for once-daily ER products

A generic sponsor should select one reference product and avoid treating all diltiazem ER products as interchangeable development targets.

What are the revenue and launch risks for a new Tiazac generic?

The revenue opportunity is constrained by mature generic competition. Expected risks include:

• Rapid price erosion after launch.
• Multiple approved strengths competing simultaneously.
• Pharmacy purchasing consolidation.
• Limited brand loyalty for an old cardiovascular product.
• Margin compression from API and capsule costs.
• Manufacturing deviations that affect dissolution.
• Delays caused by failed fed or fasting bioequivalence studies.
• Difficulty differentiating a standard generic.

A launch strategy should prioritize the highest-volume strengths, secure reliable polymer and capsule supply, and avoid unnecessary formulation novelty. A second-stage product could add a differentiated administration option or improved manufacturing economics after the core ANDA portfolio is established.

Key Takeaways

• Tiazac is an extended-release diltiazem hydrochloride capsule built around coated multiparticulate beads.
• The most relevant excipients are drug-layering binders, insoluble rate-controlling polymers, pore formers, plasticizers, anti-tacking agents, starter cores, and capsule-shell materials.
• Ethylcellulose-based coating systems are a logical starting platform because diltiazem is highly soluble and requires controlled membrane diffusion.
• The commercial opportunity is primarily generic substitution and manufacturing-cost optimization, not new-drug exclusivity.
• Tiazac has no meaningful remaining NCE exclusivity, and biosimilar risk does not apply.
• Current patent exposure should focus on formulation, process, and performance claims rather than the diltiazem molecule.
• The strongest new IP position would combine a specific multiparticulate composition with a scalable manufacturing process.
• Regulatory success depends on dissolution matching, food-effect control, alcohol dose-dumping assessment, and pharmacokinetic bioequivalence.
• The main commercial risks are price erosion, mature competition, and scale-up variability.

FAQs

Can Tiazac capsules be reformulated as tablets?

Yes, but a tablet would require a separate formulation and bioequivalence strategy. A tablet is not automatically equivalent to a multiparticulate capsule containing coated beads.

Which excipient most strongly controls Tiazac release?

The rate-controlling polymer membrane, particularly its polymer type, coating weight, pore-former level, and curing condition, usually has the greatest effect on release.

Is diltiazem hydrochloride suitable for an excipient platform product?

Yes. Its high aqueous solubility creates recurring demand for controlled-release coating technologies and makes it suitable for platform development across multiparticulate products.

Can a new manufacturer obtain patent protection for a Tiazac generic?

Patent protection may be available for a novel coating composition, release profile, alcohol-resistant system, or manufacturing method. Broad claims covering diltiazem extended release are likely to face substantial prior-art risk.

What is the lowest-risk commercial entry strategy?

The lowest-risk strategy is a conventional ANDA product using a validated coated-bead process, a focused initial strength portfolio, established excipient grades, and dissolution and pharmacokinetic performance closely aligned with the selected reference product.

References

Bausch Health. (n.d.). Tiazac: Diltiazem hydrochloride extended-release capsules prescribing information.

DailyMed. (2024). Tiazac- diltiazem hydrochloride capsule, extended release. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

U.S. Food and Drug Administration. (2019). Bioavailability and bioequivalence studies submitted in NDAs or INDs: General considerations. https://www.fda.gov/

U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book